Factive: profile and news

Oscient Pharma narrows loss on Factive sales  06 Mar 2006
Revenue growth from the launch of its bronchitis treatment drug Factive helped Oscient Pharmaceuticals Corp. narrow its net loss ... - Boston Business Journal,

Oscient Pharmaceuticals and Pfizer Enter Agreement for FACTIVE ...  Feb 7, 2006
7, 2006 - Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) has sublicensed the commercialization rights to FACTIVE(R) (gemifloxacin mesylate) tablets in ... - PharmaLive.com (press release),

Oscient Pharmaceuticals y Pfizer celebran acuerdo por las tabletas ...  Feb 7, 2006
2006 -- Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) concedió una sublicencia de los derechos de comercialización de las tabletas FACTIVE(R) (mesilato ... - Business Wire (press release),

Oscient Pharmaceuticals to Present at Fifth Annual JMP Securities ...  Mar 2, 2006
Company's President and CEO, Steven Rauscher, will provide an overview of the Company including details on the recent sublicense of FACTIVE(R) (gemifloxacin ... - Genetic Engineering News,

Pfizer acquires rights to Oscient antibiotic in Mexico  Feb 9, 2006
By Staff Writer. Biopharma company Oscient Pharmaceuticals has given Pfizer rights to commercialize its antibiotic pneumonia treatment Factive in Mexico. ... - Pharmaceutical Business Review

Oscient, Pfizer sign marketing deal  Feb 7, 2006
...said Tuesday it sublicensed the Mexican marketing rights for its Factive antibiotic tablets, used to treat community-acquired pneumonia and chronic bronchitis ... - BusinessWeek

Webcast Alert: Oscient Pharmaceuticals Announces Date for Release ...  Feb 22, 2006
The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the five-day treatment of acute bacterial exacerbations of chronic ... - Business Wire (press release),

Oscient, Pfizer sign marketing deal  Feb 7, 2006
WALTHAM, Mass. Oscient Pharmaceuticals says it sublicensed the Mexican marketing rights for its Factive antibiotic tablets to Pfizer's Mexican arm. ... - Eyewitness News,

Oscient Pharmaceuticals Acquires Expanded Worldwide Rights to Lead ...  Feb 8, 2006
The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... - Genetic Engineering News,

Robust Viral Load Reduction Successfully Achieved in Phase II ...  Feb 14, 2006
LGLS seeks to continue developing global brand products, such as Factive(R) (gemifloxacin), and expanding its market presence in the world with focus in Asia. ... - PharmaLive.com (press release),

Webcast Alert: Oscient Pharmaceuticals to Present at BIO CEO & ...  09 Feb 2006
Company's President and CEO, Steven Rauscher, will provide an overview of the Company including details on the recent sublicense of FACTIVE(R) (gemifloxacin ... - Genetic Engineering News,

Oscient Factive application accepted  Jan 20, 2006
WALTHAM, Mass. Oscient Pharmaceuticals says the FDA has accepted a marketing application for Factive as a five-day treatment for mild to moderate pneumonia. ... - Eyewitness News,

FDA Accepts for Filing Oscient Pharmaceuticals' Supplemental New ...  Jan 20, 2006
...for filing Oscient Pharmaceuticals' (Nasdaq: OSCI) supplemental New Drug Application (sNDA) seeking marketing approval for the use of FACTIVE(R) (gemifloxacin ... - Genetic Engineering News,

Oscient Pharmaceuticals Provides Preliminary Revenues for Fourth ...  Jan 9, 2006
...to record total fourth quarter revenues of approximately $9.2 million, with approximately $8 million in revenue from its lead product, FACTIVE(R) (gemifloxacin ... - Genetic Engineering News,

Oscient gets good news, bad news from FDA  Jan 20, 2006
The US Food and Drud Administration has agreed to consider allowing Oscient Pharmaceuticals' drug Factive to be used as a five-day treatment for mild to ... - Boston Business Journal,

Oscient Sees Strong Fourth-Quarter Sales  Jan 9, 2006
...$22.3 million. Boosting Oscient's performance during the period was $8 million in sales of its lead drug, Factive. The medication ... - Schaeffers Research,

Oscient sees strong 4Q sales  Jan 9, 2006
...selling drug. Boosting Oscient's performance during the period was eight (m) million dollars in sales of its lead drug, Factive. The ... - Providence Eyewitness News,

Highlights of rising and falling US stocks  Jan 20, 2006
Oscient Pharmaceuticals Corp. (OSCI) said its filing of a supplemental new drug application for the use of its Factive tablets as a five-day treatment for ... - Investor's Business Daily (subscription)

Oscient chooses Priority Solutions  Jan 31, 2006
In September 2004, Oscient launched FACTIVE fluoroquinolone antibiotic tablets for the treatment of acute bacterial exacerbations of chronic bronchitis and ... - PharmaLive.com (press release),

New Data on FACTIVE(R) Tablets and Ramoplanin Presented at the ...  Dec 9, 2005
Oscient Pharmaceuticals' (Nasdaq: OSCI) FDA-approved fluoroquinolone antibiotic, FACTIVE(R) (gemifloxacin mesylate) tablets, and lead product candidate ... - Genetic Engineering News,

Oscient Pharmaceuticals to Present at First Albany Capital Annual ...  Nov 29, 2005
President and CEO, Steven Rauscher, will provide an overview of the Company as well as an update on the market performance of FACTIVE(R) (gemifloxacin mesylate ... - Business Wire (press release),

Oscient Files Drug Application With FDA  Nov 21, 2005
...said Monday it submitted a supplemental application to the Food and Drug Administration seeking approval for the use of Factive tablets for the five-day ... - Forbes

Clinical Data on FACTIVE(R) Tablets for ABS and AECB Presented at ...  Oct 7, 2005
Society of America (IDSA) features clinical data on Oscient Pharmaceuticals' (Nasdaq: OSCI) FDA-approved fluoroquinolone antibiotic, FACTIVE(R) (gemifloxacin ... - Genetic Engineering News,

Clinical Data on FACTIVE(R) Tablets to be Presented at the 43rd ...  Sep 30, 2005
Oscient Pharmaceuticals' (Nasdaq: OSCI) FDA-approved fluoroquinolone antibiotic, FACTIVE(R) (gemifloxacin mesylate) tablets, is the subject of two poster ... - Genetic Engineering News,

Clinical Data on FACTIVE Tablets to be Presented at the 43rd ...  Sep 30, 2005
WALTHAM, Mass.--(BUSINESS WIRE)--Sep 30, 2005 - Oscient Pharmaceuticals' (Nasdaq: OSCI) FDA-approved fluoroquinolone antibiotic, FACTIVE(R) (gemifloxacin ... - PharmaLive.com (press release),

Oscient Pharmaceuticals Completes Sales Force Expansion; Company ...  Oct 3, 2005
The national sales force is focused on promoting Oscient's fluoroquinolone antibiotic, FACTIVE(R) (gemifloxacin mesylate) tablets and Auxilium Pharmaceuticals ... - Business Wire (press release),

Oscient Pharmaceuticals downgraded to "neutral weight" - update  Oct 4, 2005
In a research note published this morning, the analyst mentions that the company announced on Tuesday that it would promote FACTIVE itself, indicating its ... - New Ratings

Full Results Released From Phase III Trial Comparing Five-Day and ...  Sep 18, 2005
Data from the study of Oscient Pharmaceuticals' (Nasdaq: OSCI) FDA-approved fluoroquinolone antibiotic, FACTIVE(R) (gemifloxacin mesylate) tablets, for the ... - RedNova.com,

Oscient Pharmaceuticals Files Shelf Registration Statement  Sep 30, 2005
The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... - Genetic Engineering News,

Full Results Released from Phase III Trial Comparing Five-Day and ...  Sep 18, 2005
...(PressMethod) - Data from the study of Oscient Pharmaceuticals' (Nasdaq: OSCI - News) FDA-approved fluoroquinolone antibiotic, FACTIVE® (gemifloxacin mesylate ... - Press Method (press release),

Oscient Pharma bolsters sales force  Oct 3, 2005
The sales force will be focused on promoting Oscient's antibiotic Factive and Auxilium Pharmaceuticals' Testim testosterone gel, a testosterone replacement ... - Boston Business Journal,

Full Results Released from Phase III Trial Comparing Five-Day and ...  Sep 19, 2005
BUSINESS WIRE)--Sep 18, 2005 - Data from the study of Oscient Pharmaceuticals' (Nasdaq: OSCI) FDA-approved fluoroquinolone antibiotic, FACTIVE(R) (gemifloxacin ... - PharmaLive.com (press release),

Business in Asia -- Sept. 29, 2005  Sep 29, 2005
Under the deal, the Japanese company will have an exclusive right to sell the antibiotic drug Factive after winning approval from Japanese authorities. ... - Yahoo! News (press release)

Metabasis Advancing Internal Programs With $41M Funding  Oct 3, 2005
...its products. The national sales force is focused on promoting the antibiotic Factive, as well as Testim testosterone gel. Tessera ... - BioWorld Online (subscription),

Many meds don't mix with the sun  Sep 21, 2005
...de-meclocycline (Declomycin), doxycycline (Vibramycin) ethio-namide (Trecator-SC), flucytosine (Ancobon), gemifloxacin (Factive), griseofulvin (Fulvicin, Gris ... - Pioneer Press,

Oscient Pharmaceuticals to Present at Thomas Weisel Healthcare ...  Sep 2, 2005
President and CEO, Steven Rauscher, will provide an overview of the Company as well as an update on the market performance of FACTIVE(R) (gemifloxacin mesylate ... - Genetic Engineering News,

Morality as a Mental State  Aug 29, 2005
Morality is not a factive attitude. ... Since knowing is a factive attitude, the truth it relates to is the contingently true nature of moral propositions. ... - Global Politician,

Can Aspen continue it’s sterling performance? - Monique Vanek  Aug 22, 2005
Aspen’s CEO Stephen Saad attributed the growth to the launch of significant number of new products such as Factive, used for respiratory tract infections ... - Moneyweb,

Aspen - Reviewed Preliminary Group Financial Results For The Year ...  Aug 22, 2005
The product launches included the new chemical entity Gemifloxacillin Mesylate, specific for respiratory tract infections, marketed under the trademark Factive ... - Finance24,

Oscient Pharmaceuticals Reports Financial Results for Second ...  Aug 2, 2005
During this period, the Company recorded $4.2 million in total revenue, with $3.8 million from sales of the Company's lead product, FACTIVE (R) (gemifloxacin ... - Business Wire (press release)

Pharma Oscient sees higher revenue, wider losses in Q2  Aug 2, 2005
...reported higher revenue but also larger net losses for its 2005 second quarter, driven by expenses relating to its bronchitis/pneumonia treatment Factive. ... - Boston Business Journal

Developing a life sciences hub  Jul 28, 2005
He started work on the project's 304th candidate antibiotic which proved a potent and well tolerated medicine, which LGLS called ``Factive''. ... - Bangkok Post

Oscient Pharmaceuticals Announces Transition of Chairman of Board ...  Jul 20, 2005
...assets of our companies, recruited additional highly regarded members to our Board and put in place an experienced management team that launched FACTIVE(R) and ... - Genetic Engineering News

Webcast Alert: Oscient Pharmaceuticals Announces Date for Release ...  Jul 19, 2005
The Company is marketing FACTIVE(R) (gemifloxacin mesylate) tablets, approved by the FDA for the treatment of acute bacterial exacerbations of chronic ... - Business Wire (press release)

Hobbes in the Himalayas  Jul 26, 2005
...fusion of the psychopathic with the apocalyptic—surely the essence of "terror" in our time—is transferred to America by another "factive" passage, this one ... - Atlantic Online

Factiva Added To Yahoo! Search Subscriptions  Jul 19, 2005
...a query. Once a user clicks through a Yahoo result derived from the Factive database, they will be taken to a Factiva page. Full ... - WebProNews

Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.

Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.

Concomitant administration of FACTIVE with probenecid resulted in a 45% increase in systemic exposure to gemifloxacin.

FACTIVE had no significant effect on the anticoagulant effect of warfarin in healthy subjects on stable warfarin therapy. However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.

Quinolones form chelates with alkaline earth and transition metals. The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing aluminum and magnesium. Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE. Sucralfate should not be taken within 2 hours of FACTIVE.